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Introduction. IOERT is a therapeutic variety of selective overimpression on tumoral volumes or area at relapse risk. That allows to
protect the adjacent healthy tissues. AIMS Assessment of toxicity and survival of IOERT in exclusive treatment or overimpression
of primary tumors and relapse.
Materials and methods. Retrospective study carried out between February 2008 and January 2013 in 67 patients who were admin-
istered IOERT as part of multidisciplinay treatment. 61.2% were women and 38.8% men. The median age was 65 years (range
31–91). The classiﬁcation according to the localization was: 32.8% breast, 38.8% colon-rectal, limb 13.5%, gynaecological 3% and
pancreas 4.5%. 56.7% were administered RIO as primary treatment, 7 as overimpression (9Gy) and 13 as exclusive (21Gy). 83.6%
showed R0 after surgery. The most frequently applicator was 6 cm (34.4%) and the electron energy 4–15MeV. The dose varies
according to the intention (9–21Gy) and the surgical margin. 25.4% were administered later external radiotherapy as adjuvant
treatment (median 44Gy).
Result. With a follow up of 60 month, the current overall survival is 77.6%. The disease free survival (DFS) and metastasis (DFM)
is 80.6% and 85.1% respectively. The current local control is 91% with a trend towards signiﬁcance between primary and relapse
(p=0.074). Of the patients with relapse after treatment, 60% received chemotherapy with progression criteria in 60%. Five of
those patients (50%) died due to surgical complications. The maximum acute toxicity was GIII: dermatitis 1.5%, genitourinary
4.5% and moderate limitation in mobility was 3%. Two patients presented neuropathic pain GIII with improvement one month
after treatment end. No later complications have been assessed because of the short monitoring period.
Conclusions. The use of IOERT, either as a relapse or primary treatment provides an increase in the local control. It minimizes the
duration and toxicity of treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.205
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Objectives. To analyze the results in terms of local recurrence, disease free survival (DFS), cancer speciﬁc survival (CSS) and toxicity
of patients (pts) with resectable locally advanced gastric cancer treated with adjuvant radio-chemotherapy (RT-QT) in our center.
Materials and methods. Retrospective cohort study of 116 pts with resecable locally advanced gastric cancer treated with adjuvant
RT-QT in our department from April 2002 until June 2012. Median age 62.33 years old (25–84). 64.7% were men. The antrum and
distal stomach (54.3%) were the most frequent localization. Median KPS score was 100% (70–100%). Subtotal gastrectomy was
the most frequent surgical procedure (59.3%) and 88.7% were R0. A lymph node dissection including more than 12 lymph nodes
was performed in 42.2% pts. 54.3% pts had a histological intestinal subtype of adenocarcinoma. Pathological stage: Ib: 15.5%; II:
18.1%; III: 55.1%; IVa: 9.5%. Fluoropirimidines in monotherapy was the chemotherapy used most frequently. All patients were
treated with 3D conformal radiotherapy with a median dose of 45Gy (range 12.6–54)/1.8Gy using photons of 18MV. The median
interval between surgery and radiotherapy was 95 days (40–223).
Results. Median follow-up: 36.5 months (6–126). 56% pts died, 12 for reasons unrelated to gastric cancer and 17.2% due to local
recurrence. CSS and DFS at 3 and 5 years were 55.9% and 47.8%, and 50.6% and 43.6% respectively. In the univariate analysis the
stage, localization, lymph node involvement and type of resection had a signiﬁcant impact in CSS and DFS. Nausea and vomiting
(30%) were the most common acute effects followed by weight loss during treatment (35%) and enteritis and stenosis (11.2%) the
most common late effects.
Conclusion. In our experience, the results in terms of survival and toxicity in pts with resectable locally advanced gastric cancer
treated with adjuvant radio-chemotherapy are similar to those published so far in the literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.206
Patterns of failure in pancreatic cancer: Results review
M. de Torres, T. Garcia, B. Luden˜a, I. Juez, D. Gutierrez, M. Garcia, J. Martinez-pin˜eiro, F. Pereira, C. Rodriguez
Hospital de Fuenlabrada, Spain
Introduction and purpose. Pancreatic cancer is one of the malignant diseases which shows a higher failure rate with a 5 year overall
survival under 5%. The aim of this review is to analyze the patterns of relapse of patients diagnosed of pancreatic cancer and
treated with combined radiochemotherapy in our institution.
Methods. During 2011 and 2012 a total of 17 patients with pancreatic cancer have been treated with chemoradiotherapy in our
institution, (10 male, 7 female). Location of the primary tumour was pancreatic head in 13 of them and body or tail in 4. Nine
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patients received adjuvant postoperative radiochemotherapy, 1 neoadjuvant treatment and 8 radiochemotherapy as exclusive
radical treatment. Radiotherapy treatment was delivered with IMRT/IGRT technique to a total dose of 50.4Gy (1.8Gy per fraction)
and concurrent chemotherapy was based on weekly gemcitabine.
Results. At the date of our analysis 47% of patients had developed distant metastases, just 11.7% local relapse (2 patients relapsed
within the RT ﬁeld and one had a marginal relapse), 2 patients had tumour markers rise without relapse evidence and one patient
had a mixed (local and distant) pattern of failure. Five patients died and four are free of disease relapse (all these 4 belong to the
adjuvant treatment group).
Conclusion. IMRT/IGRT in combination with weekly Gemcitabine seem to be a good treatment choice as adjuvant postoperative
treatment which may decreased the local relapse rate in these patients. Local failure most frequent areas are the surrounding
vessels tissues.
http://dx.doi.org/10.1016/j.rpor.2013.03.207
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Perianal Paget’s disease is a rare entity, it has a high rate of recurrence and the prognosis is related to the presence of underlying
carcinoma. It usually affects white patients, more men than women, between 60 and 70 years. The histopathological diagnosis is
based on the existence of clear cytoplasm neoplastic cells at different levels of the epidermis, isolated or in small nests (pagetoid
pattern). After histopathologically Paget’s disease conﬁrmation and absence of invasive carcinoma, surgical wide local excision
with or without skin grafting will be considered the standard treatment. Chemotherapy or radiotherapy may be indicated.
There are publicated a small number of cases of disease, so we present this case. 79 years old male patient with no relevant
medical history, consult by erythematous and ulcerated skin lesion in perianal region with a year of evolution, accompanied by
intense itching and no improvement after several topical treatments. The biopsy was positive for perianal Paget’s disease and the
extension study was negative. Surgical resection was performed followed by skin plasty in V. Surgical margins were in contact
with the circumferential perianal edge. Subsequently received radiotherapy to the surgical bed, given 50.4Gy in 1.8Gy fractions,
positioning the patient in prone and using a PA ﬁeld and two posterior oblique with energy of 6MV.
Conclusion. Perianal Paget’s disease is a very rare disease with less than 120 cases reported worldwide. Although surgical excision
is reported by many authors to be the treatment of choice, other modalities of treatment are used increasingly but are not
standardized yet. Radiotherapy can be used as the primary therapy in patients not ﬁt or refusing surgery or as adjuvant therapy.
In this paper we presented a case of perianal Paget’s disease who was treated successfully with radiotherapy after surgery.
http://dx.doi.org/10.1016/j.rpor.2013.03.208
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Background. Oral ﬂuoropyrimidines have been shown as a therapeutic alternative to 5-Fluorouracil i.v. for concurrent radiotherapy
in rectal cancer.
Purpose. To assess acute toxicity and pathological stage after surgery depending on the dose of capecitabine per square meter, in
relation with the body surface (mg/m2/bid) in patients treated with concurrent radiotherapy.
Methods and materials. Between January 2008 and December 2012, 106 patients were treated. 43p were stage II and 63p stage III.
The mean age was 66 years. The prescription dose was 45Gy in 25 fractions. Two cycles of capecitabine were administered during
14 days starting within the 1st and 4th week. Surgery was scheduled to be performed 6-8 weeks after chemoradiotherapy. Acute
normal tissue effects were graded according to RTOG criteria.
Results. The most common symptoms were diarrhea and rectal tenesmus. The correlation between the grade of diarrhea and the
mean dose of capecitabine was as follows: No diarrhea in 35p (33%) with 838.9mg/m2/bid (SD 72.2); grade 1 in 23p (21.7%) with
810.2 (SD 77.6) and grade 2 in 48p (44.3%) with 807.1 (SD 57.3) (p=0.089). Seventy-six patients (63.2%) had not rectal tenesmus, and
received a mean dose of 823.1mg/m2/bid (SD 62.9), 10p (9.4%) had grade 1 with 827.5 (SD 65.4) and 29p (27.4%) had grade 2 with 804
(SD=79.9) (p=0.41). Due to thrombopenia, only 3p (2.8%) received one cycle of capecitabine while 103p (97.2%) received two. After
chemoradiotherapy 69.8% showed downstaging (16.7% pathological complete response) with a mean dose of 824.5mg/m2/bid
(SD 64.6), 14.6% progressive disease with 809 (SD 62.2) and 15.6% stable disease with 821.3 (SD 70.2) (p=0.4).
Conclusions. Our results show that with this oral dose of capecitabine schedule, according to body surface, in preoperative
chemoradiotherapy, has not statistically signiﬁcant differences for toxicity and pathological stage after surgery.
http://dx.doi.org/10.1016/j.rpor.2013.03.209
